NY-ESO-1 · TCR gene therapy is a treatment in which the NY-ESO-1 antigen is the target. Takara Bio provides NY-ESO-1 antigen-specific TCR transgenic T lymphocytes. In the production of this trial product, TCR gene transfer by the retroviral vector that we jointly developed with RetroNectin and Mie University will be used.
Takara Bio news release, Feb. 3, 2015
Takara Bio announces gene therapy phase I clinical studies directed to NY-ESO-1 antigen